NCT05173545View on ClinicalTrials.gov

Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 29, 2019

Primary Completion Date

October 28, 2020

Study Completion Date

October 28, 2020

Conditions
Recurrent/Refractory Lymphoma
Interventions
DRUG

Mitoxantrone Hydrochloride Liposome Injection

"Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes."

Trial Locations (1)

550000

Guizhou Cancer Hospita, Guiyang

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT05173545 - Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects | Biotech Hunter | Biotech Hunter